Anne Wojcicki has won a court-supervised bid to reacquire 23andMe’s assets for $305M via her nonprofit, TTAM Research Institute—outbidding Regeneron’s prior $256M offer.
Key details:
• Deal includes 23andMe’s consumer genetics services and Lemonaid Health.
• No changes to privacy policies; enhanced protections pledged.
• TTAM will keep data use limited to science and nonprofit research.
• Wojcicki calls it a return to the company’s mission of empowering people through genomics.
A court hearing for final approval is set for today, with closing expected in the coming weeks.
Follow MEDWIRE.AI for updates on consumer genomics and health data policy.
